Eli Lilly and Co (LLY) : Kimelman Baird scooped up 1,655 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 160,452 shares of Eli Lilly and Co which is valued at $12.2 Million.Eli Lilly and Co makes up approximately 2.27% of Kimelman Baird’s portfolio.
Other Hedge Funds, Including , Quadrature Capital Ltd sold out all of its stake in LLY during the most recent quarter. The investment firm sold 32,230 shares of LLY which is valued $2.5 Million.Edmond De Rothschild Holding S.a. boosted its stake in LLY in the latest quarter, The investment management firm added 910 additional shares and now holds a total of 6,410 shares of Eli Lilly and Co which is valued at $489,275. Eli Lilly and Co makes up approx 0.02% of Edmond De Rothschild Holding S.a.’s portfolio.Institutional Family Asset Management reduced its stake in LLY by selling 68 shares or 0.23% in the most recent quarter. The Hedge Fund company now holds 30,143 shares of LLY which is valued at $2.3 Million. Eli Lilly and Co makes up approx 0.84% of Institutional Family Asset Management’s portfolio. Smith Asset Management Group Lp sold out all of its stake in LLY during the most recent quarter. The investment firm sold 26 shares of LLY which is valued $1,940.B T Capital Management Dba Alpha Capital Management boosted its stake in LLY in the latest quarter, The investment management firm added 1,701 additional shares and now holds a total of 43,976 shares of Eli Lilly and Co which is valued at $3.3 Million. Eli Lilly and Co makes up approx 2.35% of B T Capital Management Dba Alpha Capital Management’s portfolio.
Eli Lilly and Co closed down -0.45 points or -0.60% at $74.54 with 46,21,719 shares getting traded on Wednesday. Post opening the session at $75.49, the shares hit an intraday low of $74.45 and an intraday high of $75.5 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
On the company’s financial health, Eli Lilly and Co reported $0.83 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on Apr 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $4865.10 million for the quarter, compared to analysts expectations of $4829.37 million. The company’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.87 EPS.
Many Wall Street Analysts have commented on Eli Lilly and Co. Company shares were Reiterated by Leerink Partners on May 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 101 from a previous price target of $96 .Societe Generale Initiated Eli Lilly and Co on Apr 6, 2016 to “Hold”, Price Target of the shares are set at $78.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.